[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525103":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":23,"responsibleParty":39,"collaborators":42,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":7,"maxAge":7,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"University of Helsinki","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"GENETIC","Biomolecular profiling","Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.",[14],{"name":15,"affiliation":16,"role":17},"Anniina Färkkilä, MD PhD","Helsinki University Central Hospital","PRINCIPAL_INVESTIGATOR",[19],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},"CONTACT","+358504272060","anniina.farkkila@helsinki.fi",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Helsinki University and Helsinki University Hospital","RECRUITING","Helsinki","00014","Finland","FI",{"type":32,"coordinates":33},"Point",[34,35],24.93545,60.16952,{"lat":35,"lon":34},[38],{"name":15,"role":20,"phone":21,"phoneExt":7,"email":22},{"type":17,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Anniina Färkkilä","Assistant Professor, Specialist in Gynecology",[43],{"name":16,"class":6},"100525103","systems-oncology-approach-to-optimize-ovarian-cancer-treatment-100525103",false,"NCT06117384","Systems Oncology Approach to Optimize Ovarian Cancer Treatment","ONCOSYS-OVA","Inclusion Criteria:\n\n* Patients diagnosed with ovarian cancer\n* Available tumor tissue\u002Fblood samples\n\nExclusion Criteria:\n\n* Inability to consent to the study","FEMALE",{"count":53,"type":54},500,"ESTIMATED","5 Years","OBSERVATIONAL","The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.",[59],"Ovarian Cancer","2023-11-01",{"date":62,"type":63},"2023-11-07","ACTUAL",{"date":65,"type":63},"2022-01-01",{"date":67,"type":54},"2027-12-31",{"name":5,"class":6},1]